Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.
| Website: | www.celldex.com |
| Email: | ir@celldextherapeutics.com |
| Main Phone: | +1 908 200-7500 |
| Address: | 53 Frontage Road |
| Address 2: | Suite 220 |
| State: | NJ |
| City / Town: | Hampton |
| Country: | US |
| Postal Code: | 08827 |
| Exchange: | NSC |
| CEO: | Anthony S. Marucci |
| Employees: | 130 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies
When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms
You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling
The recent pullback in biotech shares has not changed the time-tested theory of investing in small-cap drug development companies. Good or bad data will continue to move shares. In this interview
The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative
It’s been a big year for biotech. Heck, it’s been a big year for most of the health care sector, but biotech’s been among the biggest gainers across the entire market, with the
President Obama has been wavering on the proposed Keystone XL extension that would complete the Keystone Oil Pipeline. In a Tuesday speech, the President said “our national interest will
The Dow Industrial Average dipped to 13,139.08 then rebounded to 13,195.35 moving above its 50-day and 200-day simple moving average at 13,142.23 and 12,999.65. The Nasdaq dipped to 2971.56 than
The Labor Department reported that nonfarm payrolls rose by a slim 69,000 in May, the fewest since May 2011 and significantly below expectations. In addition the April payroll figure was revised
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.
| Website: | www.celldex.com |
| Email: | ir@celldextherapeutics.com |
| Main Phone: | +1 908 200-7500 |
| Address: | 53 Frontage Road |
| Address 2: | Suite 220 |
| State: | NJ |
| City / Town: | Hampton |
| Country: | US |
| Postal Code: | 08827 |
| Exchange: | NSC |
| CEO: | Anthony S. Marucci |
| Employees: | 130 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies
When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms
You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling
The recent pullback in biotech shares has not changed the time-tested theory of investing in small-cap drug development companies. Good or bad data will continue to move shares. In this interview
The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative
It’s been a big year for biotech. Heck, it’s been a big year for most of the health care sector, but biotech’s been among the biggest gainers across the entire market, with the
President Obama has been wavering on the proposed Keystone XL extension that would complete the Keystone Oil Pipeline. In a Tuesday speech, the President said “our national interest will
The Dow Industrial Average dipped to 13,139.08 then rebounded to 13,195.35 moving above its 50-day and 200-day simple moving average at 13,142.23 and 12,999.65. The Nasdaq dipped to 2971.56 than
The Labor Department reported that nonfarm payrolls rose by a slim 69,000 in May, the fewest since May 2011 and significantly below expectations. In addition the April payroll figure was revised
| Last Price 22.75 | Change $ 1.00 | Change % 4.60 | Tick N/A |
| Bid 22.50 | Bid Size 100.00 | Ask 22.55 | Ask Size 400.00 |
| Open 21.98 | High 23.40 | Low 21.83 | Prev Close 21.75 |
| Last Trade | Volume 285,128 | 52 Wk Hi 23.40 | 52 Wk Low 1.50 |
| Market Cap 900.2 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 39,567,065.00 | EPS (TTM) -2.18 | PE Ratio -10.00 | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 3 | 18 |
| Number of Buys | 0 | 7 |
| Number of Sells | 3 | 11 |
| Net Activity | -9005 | 34783 |
| Last 10 Buys | Shares |
|---|---|
| Tibor Keler | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Larry Ellberger | 1,000 |
| Anthony S. Marucci | 1,000 |
| Tibor Keler | 1,000 |
| Avery W. Catlin | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Avery W. Catlin | 1,000 |
| Avery W. Catlin | 1,000 |
| Avery W. Catlin | 1,000 |
| Larry Ellberger | 1,000 |
| Harry H. Penner | 1,000 |
| Karen L. Shoos | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 3 | 3 | 3 | 3 |
| Low Target Price Estimate | 1 | 1 | 1 | 1 |
| Mean Target Price Estimate | 2.05 | 2.05 | 2.05 | 2.05 |
| Standard Deviation | 1 | 1 | 1 | 1 |
| Date of Most Recent Estimate | 05/22/18 | 05/22/18 | 05/22/18 | 05/22/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-01 |
| SC 13G/A | Amendment to the SC 13G filing | 1 | 2018-05-10 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 51 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-05-10 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-02 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 62 | 2018-04-30 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-04-24 |
| CT ORDER | 1 | 2018-04-20 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 3 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 1 | 2 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2.5 | 2.5 | 1.5 | 1.8 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait